Stockreport

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai Immunotherapeutics Ltd. - American Depositary Shares  (SCNI) 
PDF Scinai files an application for Euro 12 million grant to fund next stage of developmentPincell's monoclonal antibody, PC111, is in development for treating Pemphigus, St [Read more]